Takara Bio will start mass production of cardiomyocytes from iPS cells by 2015

In collaboration with CiRA, Kyoto University, the National Institute of Health Sciences and with funding from NEDO, Takara is developing commercial mass production of myocardial cells generated from iPS cells, for use in the clinical testing of cardiac toxicity evaluation of drugs. The project is supported by NEDO with 200 million Yen.

NEDO news release, Oct. 30, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny